Mersana Therapeutics Stock - analyst consensus after takeover by Jounce owner Redx Pharma

Mersana Therapeutics is now part of the oncology portfolio of Jounce owner Redx Pharma after last year’s reverse merger. This Friday, the focus for investors is on where analyst estimates and expectations stand for the combined business following the deal.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:20 UTC. Details in the imprint.

Mersana Therapeutics (US59045L1061) has effectively become part of UK-based Redx Pharma’s oncology platform through last year’s reverse merger with Jounce Therapeutics, and the stock remains thinly covered on Wall Street. This Friday, the focus is on how analyst consensus frames the reshaped business after the transaction, based on recent data from coverage summaries.

What analysts still publish

Before the strategic restructuring, Mersana Therapeutics Inc. was followed by a small group of US biotech analysts, with consensus typically compiled on services such as MarketWatch and Nasdaq’s data pages. Coverage thinned after clinical setbacks in 2023, and some houses withdrew or suspended their ratings.

The reverse merger between Jounce Therapeutics and UK-listed Redx Pharma, announced in early 2023 and completed later that year, effectively shifted the main equity story to the combined oncology pipeline under Redx’s corporate umbrella. Dedicated Mersana targets therefore disappeared from many broker lists, and data providers now often show historic entries rather than fresh twelve-month objectives for the legacy ticker.

How consensus frames the story

Available consensus snapshots on financial portals still show the historical skew toward “Buy” or “Outperform” recommendations that characterized Mersana coverage before the setbacks, alongside at least one “Hold” stance. Those ratings rested on expectations for antibody-drug conjugate (ADC) partnerships and internal clinical programs.

After key trials were discontinued and the strategic transaction with Jounce/Redx reshaped the structure, cash-burn assumptions and probability-of-success models used in earlier notes have largely been overtaken by events. For investors, the takeaway is that historic consensus is only of limited value and that the Redx-centric research now matters more than archived Mersana tables.

The product and pipeline behind the stock

Mersana Therapeutics historically focused on antibody-drug conjugate platforms, including the Dolaflexin and Dolasynthen technologies, designed to deliver potent chemotherapy payloads directly to tumor cells while aiming to limit systemic toxicity. These assets and related know-how contributed to the rationale for combining with Jounce and Redx, which bring their own immuno-oncology and fibrosis pipelines into the mix.

Where the stock trades today

The shares of Mersana Therapeutics (US59045L1061) trade in the US as a legacy biotech listing, but current consolidated price and volume data for the restructured company are primarily reflected on Redx Pharma’s home market in London; up-to-date quote details should therefore be taken from the relevant exchange portals as of 06/19/2026, 20:20 UTC.

Key facts on Mersana Therapeutics stock

• Company: Mersana Therapeutics Inc.
• ISIN: US59045L1061
• Ticker: MRSN
• Sector / Industry: Health Care / Biotechnology

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.